Overcoming chemoresistance in triple negative breast cancer

克服三阴性乳腺癌的化疗耐药性

基本信息

  • 批准号:
    10345694
  • 负责人:
  • 金额:
    $ 9.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-12-16 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of all breast cancer patients yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by conventional chemotherapy; however, resistance to therapy is common leading to high mortality rates. Recently, we identified hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key mediator of doxorubicin resistance in TNBC (Saatci et al, Nature Communications, 2020). LOX inhibition offers a unique opportunity to re-sensitize the most aggressive breast tumors to standard-of-care chemotherapeutics. The overall objectives of this project are to (i) delineate the roles of LOX in chemoresistance, (ii) determine the mechanisms through which LOX exerts these roles, (iii) and generate prototypes of potent and selective LOX inhibitors to overcome chemoresistance in TNBC. We hypothesize that (i) LOX induces resistance not only to doxorubicin but also to other chemotherapeutic drugs by its enzymatic activity; (ii) LOX exerts this effect both by increasing collagen cross-linking/fibronectin assembly (canonical LOX function) leading to reduced drug penetration and increased integrin-mediated signaling and by regulating transcription (non-canonical LOX function) via interacting and oxidizing its substrates, culminating in activation of FAK/Src signaling and cell survival; and (iii) targeting LOX activity with selective small-molecule inhibitors will overcome chemoresistance by blocking both canonical and non-canonical LOX functions in TNBC. These hypotheses will be tested by pursuing three specific aims: 1) To determine the role of canonical ECM cross-linking function of LOX in resistance to different chemotherapeutics in TNBC. We will test the general chemosensitizer role of LOX and necessity of its enzymatic activity by generating cells with CRISPR-mediated LOX knock-out and reconstitution and testing their effects on chemoresistance in vitro and in vivo. LOX-mediated ECM changes will be analyzed by advanced microscopy techniques, e.g. MP-SHG, and the resulting drug penetration will be studied by IF and MALDI-MSI. 2) To determine the role of non-canonical transcription-regulating functions of LOX in TNBC chemoresistance. We will determine if LOX controls global transcription and identify novel LOX substrates by combining transcriptomics (RNA-Seq) and proteomics (TurboID) approaches. We will generate oxidation-deficient LOX substrates and test their effects on LOX-mediated chemoresistance. 3) To characterize novel LOX enzymatic inhibitors and test their potential as chemosensitizers in TNBC. We will test the selectivity of our inhibitors in cells with LOX knock-out/reconstitution and their off-target profiles and test their chemosensitization ability in organoids. We will perform PK/PD and toxicity profiling studies and test the inhibitors for overcoming chemoresistance in TNBC PDXs. The proposed project is expected to provide key mechanistic and phenotypic pre-clinical data to show that targeting LOX will overcome chemoresistance in the most aggressive breast cancer subtype, with a potential to reduce mortality rates.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ozgur Sahin其他文献

Ozgur Sahin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ozgur Sahin', 18)}}的其他基金

Developing novel LOX inhibitors to target chemotherapy resistant TNBC
开发新型 LOX 抑制剂以靶向化疗耐药的 TNBC
  • 批准号:
    10696810
  • 财政年份:
    2023
  • 资助金额:
    $ 9.25万
  • 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
  • 批准号:
    10670436
  • 财政年份:
    2022
  • 资助金额:
    $ 9.25万
  • 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
  • 批准号:
    10621529
  • 财政年份:
    2022
  • 资助金额:
    $ 9.25万
  • 项目类别:
Nanomechanical studies of cells and biomolecules
细胞和生物分子的纳米力学研究
  • 批准号:
    10406574
  • 财政年份:
    2022
  • 资助金额:
    $ 9.25万
  • 项目类别:
Nanomechanical studies of cells and biomolecules
细胞和生物分子的纳米力学研究
  • 批准号:
    10668957
  • 财政年份:
    2022
  • 资助金额:
    $ 9.25万
  • 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
  • 批准号:
    10298311
  • 财政年份:
    2021
  • 资助金额:
    $ 9.25万
  • 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
  • 批准号:
    10541879
  • 财政年份:
    2021
  • 资助金额:
    $ 9.25万
  • 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
  • 批准号:
    10642470
  • 财政年份:
    2021
  • 资助金额:
    $ 9.25万
  • 项目类别:
Nanomechanical imaging of protein dynamics via programmable DNA interactions
通过可编程 DNA 相互作用进行蛋白质动力学纳米力学成像
  • 批准号:
    10020421
  • 财政年份:
    2019
  • 资助金额:
    $ 9.25万
  • 项目类别:
Nanomechanical imaging of protein dynamics via programmable DNA interactions
通过可编程 DNA 相互作用进行蛋白质动力学纳米力学成像
  • 批准号:
    10217200
  • 财政年份:
    2019
  • 资助金额:
    $ 9.25万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
  • 批准号:
    DDG-2015-00002
  • 财政年份:
    2016
  • 资助金额:
    $ 9.25万
  • 项目类别:
    Discovery Development Grant
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
  • 批准号:
    DDG-2015-00002
  • 财政年份:
    2015
  • 资助金额:
    $ 9.25万
  • 项目类别:
    Discovery Development Grant
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
  • 批准号:
    9237260
  • 财政年份:
    2013
  • 资助金额:
    $ 9.25万
  • 项目类别:
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
  • 批准号:
    8657030
  • 财政年份:
    2013
  • 资助金额:
    $ 9.25万
  • 项目类别:
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
  • 批准号:
    261206-2009
  • 财政年份:
    2013
  • 资助金额:
    $ 9.25万
  • 项目类别:
    Discovery Grants Program - Individual
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
  • 批准号:
    8993725
  • 财政年份:
    2013
  • 资助金额:
    $ 9.25万
  • 项目类别:
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
  • 批准号:
    8503886
  • 财政年份:
    2013
  • 资助金额:
    $ 9.25万
  • 项目类别:
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
  • 批准号:
    261206-2009
  • 财政年份:
    2012
  • 资助金额:
    $ 9.25万
  • 项目类别:
    Discovery Grants Program - Individual
The binding and apoptosis inhibitory action to germ cells of relaxin-like peptide expressed in the boar testis
公猪睾丸表达的松弛素样肽与生殖细胞的结合及凋亡抑制作用
  • 批准号:
    24580408
  • 财政年份:
    2012
  • 资助金额:
    $ 9.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of the Insulin-like Growth Factor 2 mRNA Binding Protein (IGF2BP1) as an important regulator of cIAP1 translation and apoptosis in Rhabdomyosarcomas
鉴定胰岛素样生长因子 2 mRNA 结合蛋白 (IGF2BP1) 作为横纹肌肉瘤中 cIAP1 翻译和细胞凋亡的重要调节因子
  • 批准号:
    269093
  • 财政年份:
    2012
  • 资助金额:
    $ 9.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了